DRUGS ON THE MOVE
1. In Breast cancer
-Everolimus
-Pertuzumab
-T-DM-1
2. In Prostate cancer
-Abiraterone (Zytiga)
-Enzalutmide (Xtandi)
-Alpharadin (Radium 223)
3. Other
-Cabozantinib
-Orteronel
-Curtisen
-Tasquinimod
4. Melanoma
-Dabrafenib
-Trametinib
-GDC- 0973
-Vemurafenib (Zelboraf)
-Nivolumab
-Ipilimumab
-MK3754
5. Lung cancers
-Crizotinib
-Afatinib
-Dacomitinib
-Nivolumab
- Selumetinib
5. Thyroid cancer
-Pazopanib
A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond
Wednesday, February 27, 2013
DRUGS ON THE MOVE
Labels:
abiraterone,
alpharadin,
breast cancer,
cabozantinib,
crbcm,
curtisen,
enzalutmide,
everolimus,
lung cancers,
melanoma,
orteronel,
pertuzumab,
prostate cancer,
T-DM-1,
tasquinimod,
thyroid cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment